inclusion criteria: 1. male age ≥18 years old 2. laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization 3. clinical status on the covid-19 8-point ordinal scale of 1 or 2 4. coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln 5. subject (or legally authorized representative) gives written informed consent prior to any study screening procedures 6. subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: 1. male age ≥18 years old 2. laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization 3. clinical status on the covid-19 8-point ordinal scale of 1 or 2 4. coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln 5. subject (or legally authorized representative) gives written informed consent prior to any study screening procedures 6. subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: male age ≥18 years old laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization clinical status on the covid-19 8-point ordinal scale of 1 or 2 coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln subject (or legally authorized representative) gives written informed consent prior to any study screening procedures subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: male age ≥18 years old laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization clinical status on the covid-19 8-point ordinal scale of 1 or 2 coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln subject (or legally authorized representative) gives written informed consent prior to any study screening procedures subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: 1. male age ≥18 years old 2. laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization 3. clinical status on the covid-19 8-point ordinal scale of 1 or 2 4. coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln 5. subject (or legally authorized representative) gives written informed consent prior to any study screening procedures 6. subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: 1. male age ≥18 years old 2. laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization 3. clinical status on the covid-19 8-point ordinal scale of 1 or 2 4. coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln 5. subject (or legally authorized representative) gives written informed consent prior to any study screening procedures 6. subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: 1. male 2. age ≥50 years old 4. positive sars-cov-2 rtpcr test in the past 7 days 5. not hospitalized for acute respiratory symptoms 6. willing to provide informed consent

inclusion criteria: 1. male 2. age ≥50 years old 4. positive sars-cov-2 rtpcr test in the past 7 days 5. not hospitalized for acute respiratory symptoms 6. willing to provide informed consent

inclusion criteria: 1. male 2. age ≥50 years old 3. presenting "gabrin sign" i.e., androgenetic alopecia (norwood-hamilton grade ≥ iii) 4. positive sars-cov-2 rtpcr test in the past 7 days 5. not hospitalized for acute respiratory symptoms 6. willing to provide informed consent

inclusion criteria: 1. male 2. age ≥50 years old 3. presenting "gabrin sign" i.e., androgenetic alopecia (norwood-hamilton grade ≥ iii) 4. positive sars-cov-2 rtpcr test in the past 7 days 5. not hospitalized for acute respiratory symptoms 6. willing to provide informed consent